Literature DB >> 29769373

The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.

Antonio Scalfari1, Chiara Romualdi1, Richard S Nicholas1, Miriam Mattoscio1, Roberta Magliozzi1, Aldo Morra1, Salvatore Monaco1, Paolo A Muraro1, Massimiliano Calabrese2.   

Abstract

OBJECTIVE: To investigate the relationship among cortical radiologic changes, the number of early relapses (ERs), and the long-term course of multiple sclerosis (MS).
METHODS: In this cohort study, we assessed the number of cortical lesions (CLs) and white matter (WM) lesions and the cortical thickness (Cth) at clinical onset and after 7.9 mean years among 219 patients with relapsing remitting (RR) MS with 1 (Low-ER), 2 (Mid-ER), and ≥3 (High-ER) ERs during the first 2 years. Kaplan-Meier and Cox regression analyses investigated early factors influencing the risk of secondary progressive (SP) MS.
RESULTS: Fifty-nine patients (27%) converted to SPMS in 6.1 mean years. A larger number of CLs at onset predicted a higher risk of SPMS (hazard ratio [HR] 2.16, 4.79, and 12.3 for 2, 5, and 7 CLs, respectively, p < 0.001) and shorter latency to progression. The High-ER compared to the Low-ER and Mid-ER groups had a larger volume of WM lesions and CLs at onset, accrued more CLs, experienced more severe cortical atrophy over time, and entered the SP phase more rapidly. In the multivariate model, older age at onset (HR 1.97, p < 0.001), a larger baseline CL (HR 2.21, p = 0.005) and WM lesion (HR 1.32, p = 0.03) volume, early changes of global Cth (HR 1.36, p = 0.03), and ≥3 ERs (HR 6.08, p < 0.001) independently predicted a higher probability of SP.
CONCLUSIONS: Extensive cortical damage at onset is associated with florid inflammatory clinical activity and predisposes to a rapid occurrence of the progressive phase. Age at onset, the number of early attacks, and the extent of baseline focal cortical damage can identify groups at high risk of progression who may benefit from more active therapy.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29769373     DOI: 10.1212/WNL.0000000000005685

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

Review 1.  The immunology of multiple sclerosis.

Authors:  Kathrine E Attfield; Lise Torp Jensen; Max Kaufmann; Manuel A Friese; Lars Fugger
Journal:  Nat Rev Immunol       Date:  2022-05-04       Impact factor: 53.106

2.  Identification of early neurodegenerative pathways in progressive multiple sclerosis.

Authors:  Max Kaufmann; Anna-Lena Schaupp; Rosa Sun; Fabian Coscia; Calliope A Dendrou; Adrian Cortes; Gurman Kaur; Hayley G Evans; Annelie Mollbrink; José Fernández Navarro; Jana K Sonner; Christina Mayer; Gabriele C DeLuca; Joakim Lundeberg; Paul M Matthews; Kathrine E Attfield; Manuel A Friese; Matthias Mann; Lars Fugger
Journal:  Nat Neurosci       Date:  2022-06-20       Impact factor: 28.771

3.  Response to the letter synthetic double inversion recovery (DIR) and phase-sensitive inversion recovery (PSIR) images showed better delineation of multiple sclerosis plaques.

Authors:  Francesc Xavier Aymerich; Àlex Rovira
Journal:  Neuroradiology       Date:  2022-10       Impact factor: 2.995

4.  Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis.

Authors:  Alessandro Cagol; Sabine Schaedelin; Muhamed Barakovic; Pascal Benkert; Ramona-Alexandra Todea; Reza Rahmanzadeh; Riccardo Galbusera; Po-Jui Lu; Matthias Weigel; Lester Melie-Garcia; Esther Ruberte; Nina Siebenborn; Marco Battaglini; Ernst-Wilhelm Radue; Özgür Yaldizli; Johanna Oechtering; Tim Sinnecker; Johannes Lorscheider; Bettina Fischer-Barnicol; Stefanie Müller; Lutz Achtnichts; Jochen Vehoff; Giulio Disanto; Oliver Findling; Andrew Chan; Anke Salmen; Caroline Pot; Claire Bridel; Chiara Zecca; Tobias Derfuss; Johanna M Lieb; Luca Remonda; Franca Wagner; Maria I Vargas; Renaud Du Pasquier; Patrice H Lalive; Emanuele Pravatà; Johannes Weber; Philippe C Cattin; Claudio Gobbi; David Leppert; Ludwig Kappos; Jens Kuhle; Cristina Granziera
Journal:  JAMA Neurol       Date:  2022-07-01       Impact factor: 29.907

5.  CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis.

Authors:  Damiano Marastoni; Anna I Pisani; Gianmarco Schiavi; Valentina Mazziotti; Marco Castellaro; Agnese Tamanti; Francesca Bosello; Francesco Crescenzo; Giuseppe K Ricciardi; Stefania Montemezzi; Francesca B Pizzini; Massimiliano Calabrese
Journal:  Ther Adv Neurol Disord       Date:  2022-06-21       Impact factor: 6.430

6.  Navigator-Guided Motion and B0 Correction of T2*-Weighted Magnetic Resonance Imaging Improves Multiple Sclerosis Cortical Lesion Detection.

Authors:  Jiaen Liu; Erin S Beck; Stefano Filippini; Peter van Gelderen; Jacco A de Zwart; Gina Norato; Pascal Sati; Omar Al-Louzi; Hadar Kolb; Maxime Donadieu; Mark Morrison; Jeff H Duyn; Daniel S Reich
Journal:  Invest Radiol       Date:  2021-07-01       Impact factor: 10.065

7.  Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis.

Authors:  Max Kaufmann; Hayley Evans; Anna-Lena Schaupp; Jan Broder Engler; Gurman Kaur; Anne Willing; Nina Kursawe; Charlotte Schubert; Kathrine E Attfield; Lars Fugger; Manuel A Friese
Journal:  Med (N Y)       Date:  2021-03-12

Review 8.  Ultra-high-field 7-T MRI in multiple sclerosis and other demyelinating diseases: from pathology to clinical practice.

Authors:  Nicolo' Bruschi; Giacomo Boffa; Matilde Inglese
Journal:  Eur Radiol Exp       Date:  2020-10-22

9.  Aggressive multiple sclerosis (1): Towards a definition of the phenotype.

Authors:  Ellen Iacobaeus; Georgina Arrambide; Maria Pia Amato; Tobias Derfuss; Sandra Vukusic; Bernhard Hemmer; Mar Tintore; Lou Brundin
Journal:  Mult Scler       Date:  2020-06-12       Impact factor: 6.312

10.  Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis.

Authors:  Roshni A Desai; Andrew L Davies; Natalie Del Rossi; Mohamed Tachrount; Alex Dyson; Britta Gustavson; Pardis Kaynezhad; Lewis Mackenzie; Marieke A van der Putten; Daniel McElroy; Dimitra Schiza; Christopher Linington; Mervyn Singer; Andrew R Harvey; Ilias Tachtsidis; Xavier Golay; Kenneth J Smith
Journal:  Ann Neurol       Date:  2020-05-06       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.